{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:20:44Z","timestamp":1785943244346,"version":"3.56.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A cribriform architecture and intraductal carcinoma of the prostate (IDC-P) are recognized as aggressive histopathological features in prostate cancer. However, their prognostic significance in metastatic castration-sensitive prostate cancer (mCSPC), when assessed from diagnostic biopsy specimens, remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicenter cohort study included 131 patients with mCSPC who received doublet or triplet therapy incorporating an androgen receptor pathway inhibitor. Diagnostic prostate biopsy specimens were examined for cribriform structures and IDC-P. When the former were present, they were subclassified as small or large types. The primary endpoint was castration-resistant prostate cancer-free survival (CRPC-FS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Large cribriform structures were identified in 54.2% of patients, while small ones were observed in 19.8%. IDC-P was present in 67.2% of cases and was strongly associated with the large-type cribriform architecture (P\u00a0&amp;lt;\u00a0.001). Patients with that pattern experienced significantly shorter CRPC-FS compared to those without cribriform structures (P\u00a0=\u00a0.013), whereas the small-type architecture was not associated with disease progression. In multivariable analysis, IDC-P and an extent of disease score\u00a0\u2265\u00a03 were independently associated with shorter CRPC-FS, whereas large cribriform architecture did not retain independent significance. However, incorporation of large cribriform architecture improved model discrimination for predicting castration-resistant prostate cancer progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In diagnostic biopsy specimens, the large-type cribriform architecture is associated with adverse outcomes in mCSPC patients receiving androgen receptor pathway inhibitor-based therapy. Although its prognostic impact overlaps with that of IDC-P, its identification at diagnosis may provide clinically relevant information for contemporary mCSPC management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag067","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:21:53Z","timestamp":1775474513000},"page":"998-1006","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of large cribriform architecture and intraductal carcinoma of the prostate in diagnostic biopsies of mCSPC receiving ARPI-based therapy"],"prefix":"10.1093","volume":"56","author":[{"given":"Shun","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Pathology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo , 105-8461,","place":["Japan"]},{"name":"Department of Urology, Jikei University West Medical Center , 4-11-1, Izumihoncho, Komae-shi, Tokyo , 201-8601,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital , 1-16-36, Mizuhiki, Atsugi-shi, Kanagawa , 243-8588,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashita, Kashiwa-shi, Chiba , 277-8567,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Department of Urology, Atsugi City Hospital , 1-16-36, Mizuhiki, Atsugi-shi, Kanagawa , 243-8588,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4684","authenticated-orcid":false,"given":"Shusuke","family":"Tsuzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyaka","family":"Umemori","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University , 6-8-1, Hinode, Urayasu-shi, Chiba , 279-0013,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-8640","authenticated-orcid":false,"given":"Jun","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashita, Kashiwa-shi, Chiba , 277-8567,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5673-1553","authenticated-orcid":false,"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo , 105-8461,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026080510415392700_ref1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA."},{"key":"2026080510415392700_ref2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026080510415392700_ref3","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080510415392700_ref4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026080510415392700_ref5","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026080510415392700_ref6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet."},{"key":"2026080510415392700_ref7","doi-asserted-by":"publisher","first-page":"e70052","DOI":"10.1002\/2056-4538.70052","article-title":"Cribriform pattern and IDC-P in prostate biopsies: prognostic relevance and reporting in metastatic disease","volume":"11","author":"Okubo","year":"2025","journal-title":"J Pathol Clin Res"},{"key":"2026080510415392700_ref8","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","article-title":"ISUP consensus definition of cribriform pattern prostate cancer","volume":"45","author":"Kwast","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"2026080510415392700_ref9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14737140.2018.1469406","article-title":"Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma","volume":"18","author":"Montironi","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026080510415392700_ref10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/s41379-022-01111-w","article-title":"Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification","volume":"35","author":"Yu","year":"2022","journal-title":"Mod Pathol"},{"key":"2026080510415392700_ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051372","article-title":"Prostate cancer morphologies: cribriform pattern and intraductal carcinoma relations to adverse pathological and clinical outcomes-systematic review and meta-analysis","volume":"15","author":"Osiecki","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026080510415392700_ref12","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.clgc.2022.01.003","article-title":"Combining CAPRA-S with tumor IDC\/C features improves the prognostication of biochemical recurrence in prostate cancer patients","volume":"20","author":"Jeyapala","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2026080510415392700_ref13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080510415392700_ref14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/iju.15546","article-title":"Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: a multicenter study","volume":"31","author":"Urabe","year":"2024","journal-title":"Int J Urol"},{"key":"2026080510415392700_ref15","doi-asserted-by":"publisher","first-page":"336.e1","DOI":"10.1016\/j.urolonc.2025.02.007","article-title":"Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study","volume":"43","author":"Urabe","year":"2025","journal-title":"Urol Oncol"},{"key":"2026080510415392700_ref16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyae098","article-title":"Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study","volume":"54","author":"Urabe","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026080510415392700_ref17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080510415392700_ref18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080510415392700_ref19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/00000478-199607000-00003","article-title":"Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations","volume":"20","author":"McNeal","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"2026080510415392700_ref20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1309\/AJCPZ7WBU9YXSJPE","article-title":"Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome","volume":"136","author":"Iczkowski","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"2026080510415392700_ref21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00428-016-1981-2","article-title":"Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer","volume":"469","author":"Flood","year":"2016","journal-title":"Virchows Arch"},{"key":"2026080510415392700_ref22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"key":"2026080510415392700_ref23","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","article-title":"Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort","volume":"50","author":"Trudel","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026080510415392700_ref24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41379-022-01009-7","article-title":"Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25\u2009mm diameter as an optimal definition for \u201clarge\u201d cribriform prostatic adenocarcinoma","volume":"35","author":"Chan","year":"2022","journal-title":"Mod Pathol"},{"key":"2026080510415392700_ref25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41379-018-0157-9","article-title":"Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis","volume":"32","author":"Hollemans","year":"2019","journal-title":"Mod Pathol"},{"key":"2026080510415392700_ref26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/his.14658","article-title":"Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies","volume":"80","author":"Rijstenberg","year":"2022","journal-title":"Histopathology."},{"key":"2026080510415392700_ref27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.humpath.2023.01.008","article-title":"Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and\/or number of cores","volume":"135","author":"Okubo","year":"2023","journal-title":"Hum Pathol"},{"key":"2026080510415392700_ref28","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026","year":"2026"},{"key":"2026080510415392700_ref29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/1541-7786.MCR-18-0440","article-title":"Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate","volume":"17","author":"Elfandy","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2026080510415392700_ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313125","article-title":"Genomic features and clinical implications of intraductal carcinoma of the prostate","volume":"22","author":"Kang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026080510415392700_ref31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/0008-5472.CAN-23-1176","article-title":"Genomic and evolutionary characterization of concurrent intraductal carcinoma and adenocarcinoma of the prostate","volume":"84","author":"Zhao","year":"2024","journal-title":"Cancer Res"},{"key":"2026080510415392700_ref32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","article-title":"A prostate cancer \u201cNimbosus\u201d: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies","volume":"72","author":"Chua","year":"2017","journal-title":"Eur Urol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/998\/68130645\/hyag067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/8\/998\/68130645\/hyag067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:41:59Z","timestamp":1785940919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/8\/998\/8660388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag067","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,22]]}}}